Obesity in children is associated with increased asthma and atopy.
We sought to determine whether obesity in childhood or adolescence increases the risk of atopic dermatitis.
This retrospective, practice-based, case-control study randomly sampled 414 children and adolescents (age, 1-21 years) with atopic dermatitis between January 2000 and December 2007 and 828 randomly sampled healthy control subjects. Information was obtained from an electronic medical record. Observations were made before the a priori hypothesis.
Obesity in children is associated with increased atopic dermatitis (conditional logistic regression: odds ratio, 2.00; 95% CI, 1.22-3.26; P = .006). These atopic dermatitis-predisposing effects are found when obesity started by less than 2 years of age (adjusted odds ratio [aOR], 15.10; 95% CI, 1.51-151.21; P = .02) and 2 to 5 years (aOR, 2.58; 95% CI, 1.24-5.41; P = .01) but not greater than 5 years (aOR, 1.32; 95% CI, 0.66-2.64; P = .43) and when obesity was prolonged for 2.5 to 5 years (aOR, 2.64; 95% CI, 1.13-6.18; P = .03) and greater than 5 years (aOR, 3.40; 95% CI, 1.34-8.63; P = 0.01). Obesity is associated with more severe atopic dermatitis (ordinal logistic regression: aOR, 2.37; 95% CI, 1.24-5.37; P = .01). Obese children who eventually have atopic dermatitis require more frequent pediatrician visits for the management of atopic dermatitis (ordinal logistic regression: aOR, 2.22; 95% CI, 1.12-4.50; P = .03).
Prolonged obesity in early childhood is a risk factor for atopic dermatitis. Weight loss might be an important approach for the prevention and treatment of atopic dermatitis in children.
"In contrast to asthma, studies in children that investigate the relationship between obesity and AD are few but with controversial results  . Also data related to the role and potential significance of adipokines in AD are limited . "
[Show abstract][Hide abstract] ABSTRACT: Very little is known about the role of adipokines in atopic dermatitis (AD) in children. This study aimed at analyzing the serum levels of resistin, apelin, and visfatin in children with AD in relation to body weight, AD severity, and gender. Serum concentration of adipokines was measured in 27 children with AD and in 46 healthy subjects. Selected biochemical parameters were evaluated and skin prick test was performed. Serum levels of resistin and apelin were significantly higher, whereas serum visfatin concentration was significantly lower in children with AD versus healthy controls, although an increase in resistin levels was exclusively demonstrated in boys. In AD group, a significant increase in apelin levels in girls was documented. There was no relationship between adipokines levels and the degree of allergic sensitization. Receiver operating characteristic curve analysis demonstrated that the serum apelin cutoff value differentiating children with AD from those without was >137.8 pg/mL. Resistin and visfatin cutoff values were >3.8 ng/mL and ≤ 2.13 ng/mL, respectively. Apelin and visfatin can serve as excellent indicators to distinguish children with AD from those without disease.
Mediators of Inflammation 02/2013; 2013:760691. DOI:10.1155/2013/760691 · 3.24 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: Atopic dermatitis (AD) is a significant cause of morbidity and healthcare costs in the United States and worldwide. The prevalence of AD in childhood is rising in the United States and other developed countries for reasons that are not well understood. Similarly, the prevalences of obesity and diabetes are on the rise, which might be contributing toward increased AD. This article reviews the association between AD and other atopic disorders with obesity and diabetes. Furthermore, recently recognized AD comorbidities, including fatty liver disease and erectile dysfunction, are reviewed. Potential mechanisms for the association between AD and metabolic disorders are discussed.
[Show abstract][Hide abstract] ABSTRACT: Las características clínicas y de laboratorio de la atopia cutánea pueden relacionarse con la patogenia de las lesiones. La terapéutica de la dermatitis atópica está orientada especialmente a controlar los síntomas. Un manejo orientado a tratar al paciente según sea el mecanismo predominante de la erupción puede lograr mantener la enfermedad inactiva por largos periodos. (1, 2) Son diversas las conductas terapéuticas que pueden emplearse para el tratamiento de la atopia cutánea. En el manejo de la afección se emplean medidas 2 2 generales, técnicas del cuidado de la piel, uso de medidas de prevención y terapias tópicas y / o sistémicas que permitan aminorar las manifestaciones clínicas. (3) Dado que los factores activadores de la enfermedad son diversos, se debe adoptar medidas generales además del empleo de terapia tópica y sistémica según sea la forma de expresión de la dermatitis, así como los factores causales que estén actuando en la etapa de la enfermedad. Las medidas específicas comprenden el uso de emolientes, esteroides tópicos o inhibidores de la calcineurina, fototerapia, inmunosupresores además de otras terapias. Las nuevas posibilidades terapéuticas son las sustancias antiinflamatorias tópicas, agonistas selectivos de de los receptores de glucocorticoides, probióticos, interferón gamma, inhibidores del factor de necrosis tumoral (TNF),inhibición de las células T o B, inhibición de la unión de la IgE entre muchas otras posibilidades. (4 -6) I.-MEDIDAS GENERALES.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.